Fludarabine phosphate 50 mg / 2 ml inj: Hospital supply issue
Sandoz alerted Pharmac to an issue affecting fludarabine 50 mg / 2 ml injections (Pharmacode 2386933)
Update 27 February 2025
Shipment has arrived, it will go through release processes. The alternative remains available until the registered stock is ready for sale. It is expected to be early April.
Affected product
There is a supply issue affecting fludabarine phosphate:
- Presentation: Inj 50 mg vial
- Brand: Fludarabine Ebewe
- Pharmacode: 2386933
- Subsidy: $634.00
- Measure / Qty: per 5
It is indicated to treat chronic lymphocytic leukemia (CLL). It is primarily used to treat acute leukaemia and in conditioning prior to transplant in hospitals. It is compounded and listed under Pharmacode: 2204169. We are also working with compounders over this issue.
Schedule listing for fludarabine phosphate(external link)
HML listing for fludarabine phosphate(external link)
Alternative product
Sandoz, the supplier, is arranging a section 29 alternative which was listed from 1 June 2024. Stock is available.
Expected resolution late March 2025
Shipment has arrived, it will go through release processes. The alternative remains available until the registered stock is ready for sale. It is expected to be available late March.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)